The European Society of Medical Oncology (ESMO) annual congress convened earlier this month in Paris, where, Illumina presented key abstracts demonstrating the clinical utility of comprehensive genomic profiling (CGP). CGP is a next-generation sequencing (NGS) approach that uses a single test to assess hundreds of genes—including relevant cancer biomarkers, as established in medical guidelines and clinical trials—for tumor therapy guidance.
When it comes to carbohydrates, it’s the quality—not quantity—that matters most. With consumers taking a more holistic approach to their healthy dining habits, carbs are experiencing a resurgence in popularity.